TTrialPathMatch Me to Trials
← Back to trials
RecruitingAlzheimer DiseaseMild Cognitive Impairment (MCI)Subjective Cognitive Decline (SCD)

Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

Eligible age

55+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology among adults with subjective cognitive decline, mild cognitive impairment, or Alzheimer's disease and objective indicators of seeding AD pathology

Sponsor: Massachusetts General Hospital

You may qualify if…

  • 1. Age 55 and older, male and female;
  • 2. Subjective Cognitive Impairment or MCI or AD dementia per NIA-AA 2011 criteria;
  • 3. Clinical Dementia Rating \< or = to 2 and Mini Mental Status Exam \> or = to 16;
  • 4. Modified Hachinski Ischemic Score \< or = to 4
  • 5. Geriatric Depression Scale - 15 \< 6 documenting absence from significant depressive syndromes
  • 6. Other medications including non-disease modifying for MCI and AD (e.g., acetylcholine esterase inhibitor, N-methyl D-aspartate receptor antagonist) stable \> or = to 3-months ;
  • 7. Biomarker evidence of AD pathology: Plasma abeta42/40 ratio \< or = to 0.12 AND Plasma p-tau217 \> or = to 0.25 OR Amyloid PET positive (centiloid \> or = to 20) as part of routine clinical care.
  • 8. Sufficient vision and hearing to complete all tests

You may not qualify if…

  • 1. CDR \> 2 MMSE \< 16;
  • 2. Significant CNS disease within the last 2 years (i.e., brain tumor, seizure disorder, subdural hematoma, cranial arteritis, cortical stroke);
  • 3. Alcohol or substance abuse according to DSM-IV criteria within the last 2 years
  • 4. Major depressive disorder or anxiety within the last year; Schizophrenia, bipolar disorder or other major psychiatric disorder defined by DSM-IV criteria
  • 5. Abnormal labs indicating potential reversible causes of dementing illness such as vitamin B12 deficiency, thyroid disease, or UTI (documented bacterial colonization is acceptable)
  • 6. Unstable or significantly symptomatic CVD (e.g. CAD with frequent angina, CHF with dyspnea at rest)
  • 7. Hypertension: defined as uncontrolled BP \> 160/100
  • 8. Clinical symptomatic orthostatic hypotension

Where it's recruiting

Source: ClinicalTrials.gov · NCT07236190 · last updated 2026-06-08

Biomarker-based Trial of NPC-1 for Alzheimer's Pathology · TrialPath